Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.
about
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeysCharacterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometric peptide mapping analysisExtreme sequence divergence but conserved ligand-binding specificity in Streptococcus pyogenes M proteinEnhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.Mechanisms of immune escape in viral hepatitis.Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitutionMutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.Back to the future: covalent epitope-based HIV vaccine development.Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo.Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structureResidues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors.Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.A single gp120 residue can affect HIV-1 tropism in macaques.
P2860
Q28217208-9DA185C3-9009-42C8-A20B-2A21CE768C51Q28751926-83A2C7BF-2019-4BB1-B282-98788D6EB569Q30855134-4906F0AB-8294-4D29-84BF-0DAC882E1414Q33245070-A3EBAB33-F971-4070-994F-ADECA0351713Q33313394-9BC9917C-4E7E-4378-A259-69F335236E11Q33594871-1A361455-750B-4E3E-9C2D-E2BF4F57B0BFQ33719511-7D1DB442-7314-4EED-A548-D7E8D0985BC5Q33778466-5CA167EC-357F-4C78-AB02-87AEE9806032Q33783763-F9072BF8-C181-429D-AD10-87D516C4D0BFQ33794954-F0CA779B-60B1-4C2E-944A-30C2B24BA146Q33803590-9F5B642D-EC06-479A-A8F9-8B386B8C603BQ33814693-58BB64B1-D499-4135-A487-BD3E3F520E2CQ33839485-19E8E1E9-B563-4264-BDFD-3934B463AED4Q34359035-DF4AE1DD-70BB-4EFB-B537-E6B265BC18A1Q34529347-994A1C54-AAFA-484A-98D7-73EEE553C48EQ34597300-100C30F0-5C13-4A25-A916-26407BCE2E82Q34647680-A0029948-D40B-41AC-B972-C4DD2C8773CEQ34990575-CE6DFE7E-23F5-4E82-B2F2-A14B04935784Q34999724-CD5F2262-26E8-479F-B245-2FD7A3DFB1B5Q35105006-C827FDE4-736E-46DB-A8B1-A3B835498222Q36898925-AE0B22E0-F5D6-4414-9717-6B1EE36EFC25Q37363517-0792199D-0371-45DB-B0A5-636095B22447Q39588870-E7DE7223-2471-495D-BECE-E00594C573F6Q40399853-6A988D38-1632-4659-AE05-0999258A06E5Q40721814-383AB628-B995-411C-8C2D-BB9739362BF0Q41930708-16573047-C0E7-4860-9D9F-069D501CA947
P2860
Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Resistance of human immunodefi ...... ody binding at multiple sites.
@ast
Resistance of human immunodefi ...... ody binding at multiple sites.
@en
type
label
Resistance of human immunodefi ...... ody binding at multiple sites.
@ast
Resistance of human immunodefi ...... ody binding at multiple sites.
@en
prefLabel
Resistance of human immunodefi ...... ody binding at multiple sites.
@ast
Resistance of human immunodefi ...... ody binding at multiple sites.
@en
P2093
P2860
P1433
P1476
Resistance of human immunodefi ...... ody binding at multiple sites.
@en
P2093
Reitz MS Jr
Robert-Guroff M
Robinson J
Watkins BA
P2860
P304
P407
P577
1996-12-01T00:00:00Z